Trial Updates

TICH-NOAC: tranexamic acid for the treatment of novel oral anticoagulant-associated ICH 9:12
TICH-NOAC: tranexamic acid for the treatment of novel oral anticoagulant-associated ICH
Nils Peters et al. • 4 May 2022
MIROCALS: low-dosage IL-2 for the treatment of ALS 2:13
MIROCALS: low-dosage IL-2 for the treatment of ALS
Nigel Leigh • 17 Mar 2022
Highlights in stroke: pollution exposure, tenecteplase, and tranexamic acid 2:06
Highlights in stroke: pollution exposure, tenecteplase, and tranexamic acid
Thorsten Steiner • 6 May 2022
Thrombectomy associated with significant benefits in basilar artery occlusion… what’s next? 2:33
Thrombectomy associated with significant benefits in basilar artery occlusion… what’s next?
Raul Nogueira • 5 May 2022
ParaNASPP: prehospital NIHSS and paramedic training for improved stroke triage 8:06
ParaNASPP: prehospital NIHSS and paramedic training for improved stroke triage
Helge Fagerheim Bugge et al. • 5 May 2022
Novel agents to control seizures & target epileptogenesis 1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade • 24 Mar 2022
Early and sustained responses to cenobamate across focal seizure subtypes 7:01
Early and sustained responses to cenobamate across focal seizure subtypes
William E. Rosenfeld • 4 Apr 2022
Real-world studies of CGRP monoclonal antibodies and gepants for migraine 5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang • 3 Apr 2022
Cenobamate plasma concentrations in 50% and 100% responders 4:46
Cenobamate plasma concentrations in 50% and 100% responders
William E. Rosenfeld • 4 Apr 2022
Cognitive and psychiatric adverse events associated with cenobamate 2:38
Cognitive and psychiatric adverse events associated with cenobamate
William E. Rosenfeld • 4 Apr 2022
Intra-arterial alteplase versus placebo after mechanical thrombectomy 8:52
Intra-arterial alteplase versus placebo after mechanical thrombectomy
Ángel Chamorro • 29 Apr 2022
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis 2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr. • 12 Apr 2022
ACTIMIS: Glenzocimab add-on therapy reduces hemorrhage and mortality in ischemic stroke 4:07
ACTIMIS: Glenzocimab add-on therapy reduces hemorrhage and mortality in ischemic stroke
Mikael Mazighi • 9 May 2022
Endovascular therapy in basilar artery occlusion: the story so far 5:15
Endovascular therapy in basilar artery occlusion: the story so far
Raul Nogueira • 5 May 2022
New data supports use of tenecteplase versus alteplase 1:45
New data supports use of tenecteplase versus alteplase
Aristeidis Katsanos • 5 May 2022
Key Updates from ESOC 2022 1:04
Key Updates from ESOC 2022
Aristeidis Katsanos • 5 May 2022
The content of VJNeurology is intended for healthcare professionals